Navigation Links
Large Study Finds No Need to Screen HIV-positive Patients for Thyroid Disease

Rates of thyroid disease are similar in HIV-positive patients and the general population, according to a large British// study published in the January edition of HIV Medicine. The study’s authors, from London’s Royal Free Hospital, therefore believe that HIV-positive patients do not require thyroid screens as part of their routine HIV care.

HIV infection and treatment with potent antiretroviral therapy have been linked with various hormonal abnormalities, including diabetes and osteoporosis. Recently, some (but not all) studies have suggested a possible link between HIV infection and its treatment with thyroid disease, which can include underactivity (hypothyroidism) and overactivity (hyperthyroidism or thyrotoxicosis).

To clarify further the relationships between thyroid disease, HIV infection and potent anti-HIV therapy, a team at the Royal Free Hospital, London, examined previous thyroid function test results of 1,565 of their patients, 58% of whom were taking anti-HIV treatment.

A total of 39 individuals (2.5%) were found to have overt hypothyroidism and 61 (4%) had subclinical hypothyroidism. Eight people (<1%) had overt hyperthyroidism, five (<1%) had subclinical hyperthyroidism, and 263 (17%) had a non-thyroidal illness that had caused some changes to their thyroid function tests. Repeated measurements were available over three years for 825 patients and only eight new cases of overt thyroid disease occurred. During this period, only one of the group started anti-HIV therapy.

Although patients with overt hypothyroidism tended to be women and older, these associations also hold for the general population. Further analysis found that overt hypothyroidism was also linked with heterosexual risk, use of potent anti-HIV therapy, an AIDS diagnosis, and lower CD4 counts. However, multivariate analysis indicated that the links with markers of progressed disease (AIDS diagnosis and lower CD4 cell counts) were explain ed by the associations with gender and risk group. Thus, they did not detect any variables that were significantly and independently associated with hypothyroidism.

“There is no clear evidence that either subclinical hypothyroidism or subclinical hyperthyroidism should be treated. Recommendations in current guidelines are not to treat, and therefore the value of identifying subclinical disease that progresses slowly (if at all) to a clinical disease is questionable,” the authors write.

Further, the team suggests that, until the results of larger studies are available, “it is wise to be cautious before drawing conclusions regarding thyroid dysfunction and HIV . . . However, our study implies that the prevalence of overt thyroid disease is likely to be similar to that observed in HIV-negative populations and that routine screening of this specific population is not necessary, especially given that patients with overt clinical disease do present clinically and that [thyroid function tests] are a test clinicians have a low threshold for performing.”

Source-Bio-Bio TechnologySRM
'"/>




Related medicine news :

1. The Link Between Larger Birth Weight And Cancer Risk
2. Worlds Largest Cord Blood Bank to be started in India
3. India Has The Oldest And Largest Collection Of Preserved Mosquitoes – Mosquito Museu
4. Fear Of Dengue Epidemic Looms Large: Fever Kills Five in Pakistan
5. Visualization Found To Be Largely Dependent On The Brain
6. Large Scale Study On H5N1 Conducted
7. Large Scale Multiple Sclerosis Vaccine Trial to Be Initiated By PharmaFrontiers
8. Pre-eclampsia Pronounced With Intake of Vitamins in Large Doses
9. Large Ambulances To Handle Obese patients In Vegas
10. Heart Related Problems-The Largest Killers In Andhra Pradesh
11. Large scale culling of poultry effected at Cote dIvoire following bird flu outbreak.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: